Cheshire, UK--(Marketwire - August 13, 2007) -

                                 Protherics PLC

                      Notification of Director's Interests
London, UK; Brentwood, TN, US: 13 August 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that Rolf Soderstrom, who was appointed as Finance Director of the Company on 10 August 2007, has been granted options to subscribe for 423,076 ordinary shares in the Company under the terms of the Company's Long-Term Incentive Plan. The options were granted on 10 August 2007 and are exercisable between the third and tenth anniversary of the date of grant at a price of 2p per ordinary share, subject to the achievement of performance conditions.

The current issued ordinary share capital of the Company is 339,243,653 shares.

                                   |  Ends  |

For further information please contact:

Nick Staples, Director of Corporate Affairs         +44 (0) 7919  480510
Julie Vickers, Company Secretary                    +44 (0)1928 518010

Financial Dynamics - press enquiries
London: Ben Atwell, Anna Keeble                     +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt             +1 212 850 5600

Or visit

                      This information is provided by RNS
            The company news service from the London Stock Exchange